Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q3 2025 Earnings Presentation
31 slides from Genedx's earnings presentation, Oct 28, 2025
Slide 1: 3Q 2025 Earnings Presentation
GeneDx (Nasdaq: WGS) 3Q 2025 Earnings Presentation October 28, 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market
Slide 3: Third Quarter 2025 Results
Third Quarter 2025 Results1 Grew revenues to $116.7 million, an increase of 52%2 year-over-year Grew exome and genome test revenue to $98.9 million, an increase of 65% year-over-year Delivered adjusted gross margin of 74%, up from 64% in the third quarter of 2024 Generated adjusted net income of $14
Slide 4: Third Quarter Business Highlights
Third Quarter Business Highlights Granted FDA Breakthrough Device Designation for the GeneDx ExomeDx and GenomeDx Announced participation in two flagship genomic newborn screening initiatives – the NIH's BEACONS Initiative and Florida’s Sunshine Genetics Network Introduced GeneDx InfinityTM and exhi
Slide 5: Continued strong exome and genome volume growth and mix shift
Continued strong exome and genome volume growth and mix shift • Grew Q3 2025 exome and genome volume 33% year-over-year • Grew mix share for exome and genome to 43% of all tests reported Quarterly Exome and Genome Volume Exome and Genome Volume Mix 25,702 43% 19,262 33% 23% 13,216 5
Slide 6: Delivered our fifth consecutive profitable quarter
Delivered our fifth consecutive profitable quarter Quarterly Adj. Net (Loss)/Income 1 (in millions) • Generated third quarter 2025 adjusted net income1 of $14.7 million • Delivered fifth consecutive quarter of adjusted net income1 • Cash, cash equivalents, marketable securities and restricted cash w
Slide 7: Strategically investing to accelerate long-term growth drivers
Strategically investing to accelerate long-term growth drivers • Q3 2025 adjusted total operating expenses were $71 million • Investments reflect confidence in strategies that can drive sustained, profitable volume growth Strategic investment areas: Next Gen Peds Broadening Brand R&D and Generation
Slide 8: Full Year 2025 Guidance
Full Year 2025 Guidance1 Metric Previous Guidance Updated Guidance Revenue $400 to $415 million $425 to $428 million Growth in exome and genome revenue 48% to 52% 53% to 55% Growth in exome and genome volume At least 30% At least 30% Adjusted gross margin 68% to 71% 70% to 71% Adjusted net income Po
Slide 9: We envision a world where any genetic disorder is diagnosed quickly
We envision a world where any genetic disorder is diagnosed quickly to prevent disease progression and ensure long and healthy lives for all. 9
Slide 10: The diagnostic odyssey: common, critical, and costly
The journey to an accurate diagnosis can take up to five years.1 3x On their journey to a The diagnostic odyssey: diagnosis, rare disease common, critical, and costly patients will be misdiagnosed an average of three times.2 Millions of Americans with a rare 5 years disease are urgently searching fo
Slide 11: We prevent the unnecessary diagnostic journey
We prevent the unnecessary diagnostic journey On average: 16 tests and 5 years before an accurate diagnosis X X X X X X X X X 1 year 3 years 5 years GeneDx provides answers in months weeks days 2 years 4 years hours X X X X X X References: 1. National Orga niza tion for Rare Disord ers (NORD). Hope
Slide 12: Exome and genome testing offer answers sooner, leading to more effective treatments
Exome and genome testing offer answers sooner, leading to more effective treatments and more efficient healthcare spend – now recognized by AAP Recommended by leading medical Superior diagnostic rate for many indications including: societies as a first-line test: Developmental delay American College
Slide 13: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% of epilepsy genes are tested on many commercial epilepsy panels 13 Reference: Butler L. et al. Exome-based testing for patients with seizures: Adva
Slide 14: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% of epilepsy genes are tested on many commercial epilepsy panels Exome and genome sequencing checks all 768 genes 14 Reference: Butler L. et al. Exo
Slide 15: GeneDx has spent over a decade solving for the limitations of the past
GeneDx has spent over a decade solving for the limitations of the past and we're working to change the perception of exome and genome sequencing Then Now Results take months GeneDx delivers results in hours, days or weeks Turnaround time GeneDx’s tests are accessible and widely Tests are prohibitive
Slide 16: Our north star: to diagnose disease earlier for as many families as possible
Our north star: to diagnose disease earlier for as many families as possible Fastest growing Best in class Build the and profitable diagnosis network effect Leveraging the GeneDx Infinity to fuel growth and generate deep genomic insights 16
Slide 17: With every patient, we accelerate and widen our competitive advantage
With every patient, we accelerate and widen our competitive advantage Additional patients Higher tested diagnostic yield and more answers for more patients ~1M >7M >2.5M exomes & phenotypic genetic genomes datapoints tests More Improved underlying interpretation data platform 17
Slide 18: Solidifying our leadership and competitive advantage
Solidifying our leadership and competitive advantage We are the #1 genomic testing brand among pediatric and genetic providers1 – here's why: GeneDx InfinityTM Team of Experts Technology Our unmatched dataset With >100 MD and/or PhDs Our AI-driven fuels deeper insights and and >150 genetic counselor
Slide 19: We are increasing market adoption through breadth and depth
We are increasing market adoption through breadth and depth We will expand target market segments and clinical indications to open access to additional patients over time Patient Current Market Total Future Market Market Segment Number of Targets Opportunity Penetration (Patients) Opportunity* Newbo
Slide 20: Fueling growth and better outcomes in the outpatient setting
Fueling growth and better outcomes in the outpatient setting Growing from the core: • Scaling utilization by geneticists and pediatric neurologists diagnosing epilepsy, autism and intellectual disability/developmental delay, and rare disease Expanding to new indications: • Started with cerebral pals
Slide 21: Delivering answers to improve care in the NICU
Delivering answers to improve care in the NICU Demonstrating clinical and economic utility: • SeqFirst: 60% of infants in Level IV NICUs should receive a rapid genome test1 • Genome testing is severely underutilized, currently ordered for <5% of children who could benefit 2 • A genetic diagnosis in
Slide 22: We are radically simplifying genomics to enable broad adoption in everyday medicine
We are radically simplifying genomics to enable broad adoption in everyday medicine Meet customers where they are with a one-minute order and best-in-class customer experience PRE-2025 H1 2025 H2 2025 2026 An Experience Built AAP Guidance Opens Gen Peds Research Roll Out CX for Geneticists the Gen P
Slide 23: Payor coverage for exome and genome sequencing is expanding
Payor coverage for exome and genome sequencing is expanding 〉 GeneDx is contracted with 80% of covered lives, including all large national commercial payers 〉 Medicaid and commercial insurance coverage continues to grow for exome and genome o 36 states cover exome or genome testing • In Q3, Californ
Slide 24: Medicaid programs across the country are expanding access
Medicaid programs across the country are expanding access Current Medicaid Coverage Landscape Exome or Genome Sequencing Rapid Genome Sequencing Both No Coverage New or Enhanced Coverage 24 Data through October 2025
Slide 25: GeneDx is revolutionizing the standard approach to newborn screening
GeneDx is revolutionizing the standard approach to newborn screening, enabling actionable diagnoses before symptoms even start GUARDIAN has laid the foundation of clinical evidence • Screened 20,000 healthy infants with goal of >100,000 Genomic newborn screening (gNBS) • 3.2% true positive rate, and
Slide 26: Creating the network effect that will drive the future of precision medicine
Creating the network effect that will drive the future of precision medicine Patients Biopharma Delivering faster, more accurate diagnosis Accelerating drug discovery, enabling with personalized treatments based on clinical trials, and unlocking biomarkers for biology, leading to better outcomes tar
Slide 27: Genetic evidence is one of the most powerful tools to improve therapeutic development
Genetic evidence is one of the most powerful tools to improve the therapeutic development process Tomorrow Today Including genetic evidence can The average therapeutic dramatically reduce cost, shorten development cycle: timelines, and improve success rates: Costs $2.6B Genetic evidence can reduce o
Slide 28: A rare opportunity to fuel seismic healthcare shifts
A rare opportunity to fuel seismic healthcare shifts From years of disease progression early interventions From unnecessary and bloated health costs streamlined economic efficiency to From generalized treatments precision medicines From diagnosing symptomatic disease universal genomic newborn screen
Slide 29: The future of healthcare is about proactive, personalized care
The future of healthcare is about proactive, personalized care. GeneDx is leading the way. 29
Slide 30: Appendix
Appendix 30 Confidential & Proprietary. Do Not Distribute.
Slide 31: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures Adjusted gross profit and adjusted gross margin (in $ thousands) Three months ended September 30, 2025 2024 GeneDx Other 1 Total GeneDx Other 1 Total Revenue $ 114,697 $ 2,046 $ 116,743 $ 76,622 $ 252 $ 76,874 Adjusted cost of services 30,246 377 30,623